Google
 
Web www.vitaminlore.com
www.eniva.com

Raloxifene

Also indexed as: Evista®

Raloxifene is a type of drug called a selective estrogen receptor modulator (SERM). It is used to prevent osteoporosis in women after menopause.

Interactions with Herbs

Formononetin
Some chemicals called phytoestrogens, found naturally in plants, have estrogen-like activity; and some people use these phytoestrogens from dietary sources or from supplements to prevent or treat hormone-related health problems. In test tube studies, the estrogenic activity of one phytoestrogen, formononetin, was blocked by raloxifene.1 Further research is necessary to determine the overall effect of raloxifene on formononetin and other phytoestrogens in humans.

Summary of Interactions for Raloxifene

Depletion or interference Phytoestrogens
Adverse interaction None known
Side effect reduction/prevention None known
Supportive interaction None known
Reduced drug absorption/bioavailability None known

For the convenience of the reader, the information in the summary is categorized as follows: “Depletion or interference” indicates the drug may deplete or interfere with the absorption or function of the supplement or herb. “Adverse interaction” indicates that the supplement or herb used together with the drug may result in undesirable effects. “Side effect reduction/prevention” indicates the supplement or herb may reduce the likelihood and/or severity of a potential side effect caused by the drug. “Supportive interaction” indicates the supplement or herb may support or aid the function of the drug. “Reduced drug absorption/bioavailability” indicates that the supplement or herb may decrease the absorption and/or activity of the drug in the body. An asterisk (*) next to an item in the summary indicates that the interaction is supported only by weak, fragmentary, and/or contradictory scientific evidence.

References:

1. Ruh MF, Taylor JA, Howlett AC, Welshons WV. Failure of cannabinoid compounds to stimulate estrogen receptors. Biochem Pharmacol 1997;53:35–41.